Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | DESTINY-Breast04: T-DXd for patients with HER2-low mBC

Lajos Pusztai • 6 Jun 2022
ASCO 2022
Breast Cancer Antibodies Trastuzumab deruxtecan
DESTINY-Breast04

Lajos Pusztai, MD, DPhil, Yale School of Medicine, New Haven, CT, talks on the Phase III DESTINY-Breast04 trial (NCT03734029) which explored trastuzumab deruxtecan versus investigator’s choice of chemotherapy for HER2-low metastatic breast cancer that has spread or cannot be surgically removed. Following the encouraging results of the DESTINY-Breast04, demonstrating impressive progression-free survival (PFS) and overall-survival (OS) with trastuzumab deruxtecan, the HER2-targeted antibody-drug conjugate (ADC) is set to become the new standard of care for patients with HER2-low breast cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Lajos Pusztai

Development of RSClin N+, a quantitative tool for assessing breast cancer risk
1:17
Development of RSClin N+, a quantitative tool for assessing breast cancer risk
Lajos Pusztai • 3 Jun 2024
RSClin N+ in planning treatment for lymph node-positive breast cancer
1:33
RSClin N+ in planning treatment for lymph node-positive breast cancer
Lajos Pusztai • 3 Jun 2024
SWOG S1207: adjuvant ET +1 yr everolimus shows benefit in premenopausal high-risk HR+/HER2- BC
1:59
SWOG S1207: adjuvant ET +1 yr everolimus shows benefit in premenopausal high-risk HR+/HER2- BC
Lajos Pusztai • 8 Dec 2022
The molecular differences between younger versus older ER-positive and HER2-negative breast cancers
3:08
The molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Lajos Pusztai • 8 Dec 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals